Dover has entered into a definitive settlement to acquire Malema Engineering Corp, a US designer and producer of high-precision, mission-critical flow-measurement and management devices for the biopharmaceutical, semiconductor and industrial sectors.
เกวัดแรงดัน will expand Dover’s biopharma single-use production offering, which already includes Quattroflow pumps, CPC connectors, and em-tec flowmeters.
Based in Boca Raton, Florida, and with amenities in San Jose, California, Singapore, South Korea and India, Malema expects to generate roughly US$40 million–45 million in revenue through the full year 2022.
When the deal closes, Malema will become a half of the PSG business unit within Dover’s Pumps & Process Solutions section.
“We see an amazing long-term progress alternative within the bioprocessing industry pushed by a strong and rising pipeline of effective novel biologic medication, biosimilars, protein therapies, non-COVID mRNA vaccines, in addition to budding cell & gene therapies,” says PSG’s president Karl Buscher. “Additionally, the rising adoption of more environment friendly single-use production processes supports a strong outlook for our choices of single-use components to end-customers. We believe that pairing Malema’s expertise with our present portfolio of single-use pumps for biopharma processing will greatly enhance the accuracy and worth proposition of our options to our clients.”
“We are methodically constructing out our biopharma platform by way of proactive capability additions, new product improvement, and opportunistic acquisitions of highly-attractive niche part applied sciences,” said Richard Tobin, president and CEO of Dover. “Malema represents a strategic and highly-complementary flow-control and sensing expertise and further strengthens our sensor portfolio with new proprietary know-how. In addition to attractive biopharma purposes, we count on strong progress within the semiconductor space on the capacity enlargement and re-shoring tailwinds.”
Share